KALV - KalVista Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.57
+0.06 (+0.34%)
As of 2:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close17.51
Open17.55
Bid17.58 x 800
Ask17.62 x 800
Day's Range17.55 - 18.03
52 Week Range7.95 - 34.92
Volume135,129
Avg. Volume178,801
Market Cap305.512M
Beta (3Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire4 days ago

    KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

    – KVD900 Enrolling Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema with Data Expected in Late 2019 –

  • Business Wire18 days ago

     KalVista Pharmaceuticals Announces Changes to Board of Directors

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Martin Edwards has been appointed and Richard H. Aldrich is resigning from the Company’s Board of Directors. Both changes are part of a planned transition and are effective immediately.

  • Business Wirelast month

    KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors announced data was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal. “We continue recruiting for our Phase 2 clinical trial of KVD900,” said Andrew Crockett, Chief Executive Officer of KalVista.

  • Business Wire2 months ago

    KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Jefferies Healthcare Conference on Thursday, June 6, 2019, at 4:00 p.m. ET in New York, NY. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • Business Wire2 months ago

    KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data that was presented at the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. “KVD900 is an oral, novel, potent and selective inhibitor of plasma kallikrein, a validated target in hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista.

  • Business Wire2 months ago

    KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences

    – Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented –

  • Business Wire3 months ago

    KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019

    – Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice –

  • Business Wire3 months ago

    KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr. Soland most recently served as the Chief Executive Officer of uniQure N.V. and Senior Vice President and Chief Operating Officer of ViroPharma.

  • Business Wire4 months ago

    KalVista Pharmaceuticals to Present at Needham Healthcare Conference

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, at 2:10 p.m. ET in New York, NY. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • GlobeNewswire4 months ago

    Recent Analysis Shows Wells Fargo, Public Service Enterprise Group, Apartment Investment and Management, Gentherm, Connecticut Water Service, and KalVista Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire4 months ago

    KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the promotion of Ben Palleiko to Chief Business Officer in addition to his current role as Chief Financial Officer, effective immediately. “Ben has become an integral part of KalVista since joining over two years ago to help establish us as a public company and drive our financial strategy and growth,” said Andrew Crockett, Chief Executive Officer of KalVista.

  • Business Wire4 months ago

    KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

    – Oral Hereditary Angioedema Candidate KVD900 Phase 2 Trial Progressing –

  • Business Wire5 months ago

    KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019

    – KVD900 600 mg Provides >90% Inhibition of Plasma Kallikrein Within 30 Minutes of Dosing –

  • Business Wire6 months ago

    KalVista Pharmaceuticals Appoints Brian J. G. Pereira, MD to Board of Directors

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Brian Pereira has been appointed to its Board of Directors effective February 1, 2019. Dr. Pereira is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies.

  • GlobeNewswire6 months ago

    Research Report Identifies TechnipFMC plc, Glu Mobile, EPR Properties, Apartment Investment and Management, KalVista Pharmaceuticals, and DXP Enterprises with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Jan. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire6 months ago

    KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided a development update on its oral plasma kallikrein inhibitor portfolio.

  • Business Wire7 months ago

    KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

    – KVD900 Enlarged Phase 2 Trial on Track for Potential On-Demand Treatment of Attacks in Patients with Hereditary Angioedema –

  • Business Wire8 months ago

    KalVista Pharmaceuticals Provides Clinical Update on KVD900

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the hereditary angioedema (HAE) candidate KVD900. “Our first step has been to design a larger Phase 2 clinical trial for KVD900 as on-demand treatment for HAE attacks in patients to generate more robust data that we intend to use as the basis for discussions with the FDA about a faster approval pathway.

  • Business Wire8 months ago

    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

    A live webcast of the presentations may be accessed on the Investors section of the Company’s website at www.kalvista.com. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • Business Wire10 months ago

    KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 8:00 a.m. ET in New York, NY. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • Business Wire10 months ago

    KalVista Pharmaceuticals Reports Fiscal First Quarter Results

    – KVD900 Phase 2 On Track to Begin in 2018 for Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema –

  • Business Wire10 months ago

    KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the closing of its previously announced underwritten public offering of 4,600,000 shares, which included the exercise in full by the underwriters of their over-allotment option to purchase 600,000 additional shares of common stock, at a price to the public of $17.00 per share. KalVista intends to use the net proceeds from this offering to fund late stage development of KVD900, including beyond anticipated Phase 3 data and a potential larger Phase 2 trial and other activities to accelerate the timeline for a new drug application, and to support accelerated development of additional hereditary angioedema (HAE) and oral diabetic macular edema (DME) programs.

  • Business Wire10 months ago

    KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be approximately $68.0 million. The offering is expected to close on September 10, 2018, subject to customary closing conditions.

  • Business Wire10 months ago

    KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, announced today that it intends to offer shares of its common stock in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day over-allotment option to purchase additional shares of its common stock offered in the public offering at the public offering price less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.